San Mateo, CA (PRWEB) May 14, 2013
Entelos Holding Corp. (“Entelos” or “the Company”), a premier provider of physiological system modeling and services, and Seattle-based Institute for System Biology (ISB), the nonprofit pioneers of the systems approach to study the molecular causes of diseases, today announced the successful integration of gene expression data into quantitative physiological simulations. This proprietary capability improves understanding of the gene expression and disease outcomes to radically improve the predictive discernment of the complex nature of disease, yielding insights into novel therapeutic targets, biomarkers, and patient selection that should support a new era of precision medicine.
Entelos and ISB worked together to define a scientifically sound and scalable methodology to provide breakthrough capabilities for both the modeling and systems pharmacology communities. It addresses business-critical problems in both pharmaceutical research and healthcare. “This workflow is transformative for understanding the role of molecular interactions and their impact on pharmaceutical R&D and healthcare decision making,” stated Entelos Founder and CTO, Tom Paterson. “By utilizing our computer models, we are able to use all identified correlations across gene network studies to decipher genetic influence on the disruptions identified as disease. As an example, the new capabilities were able to help us clearly define from a pool of 51 potential biomarkers, and which biomarkers identified non-responders and responders for anti-IL1 therapies for rheumatoid arthritis.”
“The mapping and application of clinical gene expression data sets a new standard and role for quantitative physiological modeling within the drug discovery and development process,” stated Entelos President and CEO, Shawn O’Connor. “It’s only due to the unique depth and breadth of the Entelos quantitative physiological models that these sorts of mappings and analyses can be carried out across the entire pathophysiology of a disease. This is the beginning of truly understanding and leveraging the human genome for therapeutic success.”
“As the interconnected features of the disease space become increasingly more visible, we are continuing to look for new ways to decipher the elaborate data that hides therapeutic success,“ said Dr. Lee Hood, co-founder and president of Institute for Systems Biology and recipient of the National Medal of Science. “This approach represents a breakthrough capability for deriving insights from those data sets.”
This demonstrated convergence of top-down functional systems biology and bottom-up molecular systems biology provides an approach for using clinical gene expression data to investigate a wide diversity of diseases, to decipher disease complexity, and to understand variability and reduce uncertainty in populations and sub populations. Entelos and ISB are now seeking commercial partners to advance additional existing disease models (Atherosclerosis, Type 2 Diabetes, Hypertension, Rheumatoid Arthritis, etc.) and generate new in silico applications.
To learn more: Entelos and the ISB are hosting a public webinar on June 6, 2013. Please go to the Entelos website http://www.entelos.com/webinars/webinars-coming-up/ to register.
Entelos is an in silico modeling and simulation software and services company delivering predictive technologies reducing risk, time, and cost of product development for pharmaceutical, biotechnology, nutrition and consumer products customers. The Company's PhysioLab systems biology platforms generate virtual patient populations providing highly predictive analyses to develop safer and more effective drugs, foods and consumer products. Entelos’ understanding of patient variability has significant application to the emerging field of personalized medicine. The Company is headquartered in San Mateo, California. For more information, please visit http://www.entelos.com.
The Institute for Systems Biology (ISB) is a world-renowned, non-profit research institute headquartered in Seattle that is dedicated to the study and application of systems biology. Founded in 2000, ISB seeks to unravel the mysteries of biology while identifying strategies for predicting and preventing diseases, solving energy and environmental issues, and improving K-12 science education. ISB's systems approach integrates biology, computation and technological development, enabling scientists to analyze all elements in a biological system rather than one gene or protein at a time. ISB has 10 faculty members and about 230 staff. Learn more at http://www.systemsbiology.org.